PMC:7283670 / 107929-109337 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T16","span":{"begin":37,"end":45},"obj":"Body_part"},{"id":"T17","span":{"begin":196,"end":204},"obj":"Body_part"},{"id":"T18","span":{"begin":297,"end":301},"obj":"Body_part"},{"id":"T19","span":{"begin":484,"end":496},"obj":"Body_part"},{"id":"T20","span":{"begin":970,"end":986},"obj":"Body_part"},{"id":"T21","span":{"begin":982,"end":986},"obj":"Body_part"},{"id":"T22","span":{"begin":1215,"end":1224},"obj":"Body_part"},{"id":"T23","span":{"begin":1225,"end":1229},"obj":"Body_part"},{"id":"T24","span":{"begin":1345,"end":1350},"obj":"Body_part"}],"attributes":[{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma21185"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T205","span":{"begin":484,"end":496},"obj":"Body_part"},{"id":"T206","span":{"begin":492,"end":496},"obj":"Body_part"},{"id":"T207","span":{"begin":976,"end":981},"obj":"Body_part"}],"attributes":[{"id":"A205","pred":"uberon_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/UBERON_0001361"},{"id":"A206","pred":"uberon_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"A207","pred":"uberon_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T566","span":{"begin":64,"end":67},"obj":"Disease"},{"id":"T568","span":{"begin":72,"end":80},"obj":"Disease"},{"id":"T569","span":{"begin":191,"end":195},"obj":"Disease"}],"attributes":[{"id":"A566","pred":"mondo_id","subj":"T566","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A567","pred":"mondo_id","subj":"T566","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"},{"id":"A568","pred":"mondo_id","subj":"T568","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A569","pred":"mondo_id","subj":"T569","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T26","span":{"begin":236,"end":238},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T27","span":{"begin":492,"end":496},"obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"T28","span":{"begin":492,"end":496},"obj":"http://www.ebi.ac.uk/efo/EFO_0000816"},{"id":"T29","span":{"begin":626,"end":631},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T30","span":{"begin":976,"end":981},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T31","span":{"begin":982,"end":986},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T32","span":{"begin":1071,"end":1076},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T33","span":{"begin":1084,"end":1088},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T34","span":{"begin":1253,"end":1257},"obj":"http://purl.obolibrary.org/obo/CLO_0053704"},{"id":"T35","span":{"begin":1323,"end":1326},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T36","span":{"begin":1329,"end":1332},"obj":"http://purl.obolibrary.org/obo/CLO_0052882"},{"id":"T37","span":{"begin":1329,"end":1332},"obj":"http://purl.obolibrary.org/obo/CLO_0053434"},{"id":"T38","span":{"begin":1333,"end":1336},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T39","span":{"begin":1339,"end":1342},"obj":"http://purl.obolibrary.org/obo/CLO_0052882"},{"id":"T40","span":{"begin":1339,"end":1342},"obj":"http://purl.obolibrary.org/obo/CLO_0053434"},{"id":"T41","span":{"begin":1343,"end":1350},"obj":"http://purl.obolibrary.org/obo/CL_0000084"}],"text":"Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T72462","span":{"begin":88,"end":99},"obj":"Chemical"},{"id":"T7025","span":{"begin":349,"end":357},"obj":"Chemical"},{"id":"T65846","span":{"begin":626,"end":631},"obj":"Chemical"},{"id":"T33991","span":{"begin":800,"end":806},"obj":"Chemical"},{"id":"T19624","span":{"begin":1064,"end":1070},"obj":"Chemical"},{"id":"T15741","span":{"begin":1225,"end":1227},"obj":"Chemical"},{"id":"T28024","span":{"begin":1232,"end":1234},"obj":"Chemical"},{"id":"T87","span":{"begin":1247,"end":1249},"obj":"Chemical"},{"id":"T26286","span":{"begin":1253,"end":1255},"obj":"Chemical"}],"attributes":[{"id":"A91289","pred":"chebi_id","subj":"T72462","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A85121","pred":"chebi_id","subj":"T7025","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A53798","pred":"chebi_id","subj":"T65846","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A92500","pred":"chebi_id","subj":"T33991","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A85142","pred":"chebi_id","subj":"T19624","obj":"http://purl.obolibrary.org/obo/CHEBI_37409"},{"id":"A75184","pred":"chebi_id","subj":"T15741","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A55525","pred":"chebi_id","subj":"T15741","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A91342","pred":"chebi_id","subj":"T28024","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A7907","pred":"chebi_id","subj":"T28024","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A63351","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A8496","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A70323","pred":"chebi_id","subj":"T26286","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A86569","pred":"chebi_id","subj":"T26286","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020"}

{"project":"LitCovid-sentences","denotations":[{"id":"T922","span":{"begin":0,"end":269},"obj":"Sentence"},{"id":"T923","span":{"begin":270,"end":407},"obj":"Sentence"},{"id":"T924","span":{"begin":408,"end":483},"obj":"Sentence"},{"id":"T925","span":{"begin":484,"end":631},"obj":"Sentence"},{"id":"T926","span":{"begin":632,"end":645},"obj":"Sentence"},{"id":"T927","span":{"begin":646,"end":740},"obj":"Sentence"},{"id":"T928","span":{"begin":741,"end":817},"obj":"Sentence"},{"id":"T929","span":{"begin":818,"end":828},"obj":"Sentence"},{"id":"T930","span":{"begin":829,"end":1408},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T298","span":{"begin":37,"end":62},"obj":"Phenotype"},{"id":"T299","span":{"begin":196,"end":210},"obj":"Phenotype"},{"id":"T300","span":{"begin":790,"end":795},"obj":"Phenotype"},{"id":"T301","span":{"begin":923,"end":928},"obj":"Phenotype"}],"attributes":[{"id":"A298","pred":"hp_id","subj":"T298","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A299","pred":"hp_id","subj":"T299","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A300","pred":"hp_id","subj":"T300","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A301","pred":"hp_id","subj":"T301","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1872","span":{"begin":1225,"end":1230},"obj":"Gene"},{"id":"1873","span":{"begin":1232,"end":1237},"obj":"Gene"},{"id":"1874","span":{"begin":1247,"end":1251},"obj":"Gene"},{"id":"1875","span":{"begin":1253,"end":1257},"obj":"Gene"},{"id":"1876","span":{"begin":1262,"end":1267},"obj":"Gene"},{"id":"1877","span":{"begin":1323,"end":1326},"obj":"Gene"},{"id":"1878","span":{"begin":1333,"end":1336},"obj":"Gene"},{"id":"2036","span":{"begin":755,"end":767},"obj":"Species"},{"id":"2037","span":{"begin":888,"end":900},"obj":"Species"},{"id":"2038","span":{"begin":1053,"end":1076},"obj":"Species"},{"id":"2092","span":{"begin":408,"end":419},"obj":"Chemical"}],"attributes":[{"id":"A1872","pred":"tao:has_database_id","subj":"1872","obj":"Gene:3552"},{"id":"A1873","pred":"tao:has_database_id","subj":"1873","obj":"Gene:3586"},{"id":"A1874","pred":"tao:has_database_id","subj":"1874","obj":"Gene:3569"},{"id":"A1875","pred":"tao:has_database_id","subj":"1875","obj":"Gene:3576"},{"id":"A1876","pred":"tao:has_database_id","subj":"1876","obj":"Gene:7124"},{"id":"A1877","pred":"tao:has_database_id","subj":"1877","obj":"Gene:920"},{"id":"A1878","pred":"tao:has_database_id","subj":"1878","obj":"Gene:925"},{"id":"A2036","pred":"tao:has_database_id","subj":"2036","obj":"Tax:9606"},{"id":"A2037","pred":"tao:has_database_id","subj":"2037","obj":"Tax:9606"},{"id":"A2038","pred":"tao:has_database_id","subj":"2038","obj":"Tax:2697049"},{"id":"A2092","pred":"tao:has_database_id","subj":"2092","obj":"MESH:C502936"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020"}